Dr. Marvin Stone, Chief, Baylor Sammons Cancer Center in Dallas, Texas, and recipient of the 2004 Waldenstrom's Lifetime Achievement award with Dr. Treon following a presentation on novel treatment options for WM to the cancer center's faculty and fellows in 2008.

Download BUMC Proceedings Vol 14, number 4, Oct 2001, a conversation between Dr. Stone and the editor, William C. Roberts, MD.

Please visit our main program website: Bing Center for Waldenstrom's Research. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.

Also feel free to visit our WM Workshop Website where you will find information about our upcoming conference October 6-10, 2010 in Venice, Italy.

If this message stays visible for more than 10 seconds, then the browser you are using may not work with the contents of this page. We recommend that you update to a newer browser or check to make sure that JavaScript is enabled.

 Featured Impact Articles

In this study, Dr. Treon and colleagues reported a seven fold increased incidence of WM disease transformation to aggressive lymphoma, and a three-fold increased risk of development of acute leukemia and myelodysplasia in patients who received treatment with a nucleoside analogue (fludarabine or cladribine). This study highlights the importance of carefully weighing risk and benefit in selection of drugs used in the treatment of WM.		Representing one of the longest follow-up studies conducted in WM, this study identified that patients attaining at least a very good partial response (VGPR) had a superior time to progression over patients who did not achieve a VGPR, and highlights the importance of pursuing therapies which can result in deeper categorical response levels in WM. The study also identified increased long term risk of disease transformation and acute leukemia/myelodysplasia.
Co-chaired by Drs. Meletios Dimopoulos and Steve Treon, the consensus panel on therapeutics updated recommendations for the treatment of WM in both first-line and salvage treatments, and adopted the use of bortezomib (Velcade®) as a treatment option in view of recently published clinical trials.		This study identified that soluble CD27 (sCD27) levels are elevated in patients with WM, and stimulate mast cells to produce signals (such as CD40L and APRIL) which in turn promote the growth and survival of WM cells. The study also showed that a novel antibody (SGN-70) could be used to block sCD27 signaling and block WM disease growth in mice.

[CLM_2010.n.015] Bortezomib as a Treatment Option in Patients With Waldenstrom Macroglobulinemia.
Meletios A. Dimopoulos, Christine Chen, Efstathios Kastritis, Maria Gavriatipoulou, Steven P. Treon

[JCO.2009.25.3237v1] Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia.
Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.

[JCO.2009.24.0994v1] Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia.
Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE.

[Clin Cancer Res 2009;15(1)] Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Chu L, Musto P, Baron AD, Nunnink JC, Kash JJ, Terjanian TO, Hyman PM, Nawfel EL, Sharon DJ, Munshi NC, Anderson KC.

[haematol.2009.010348] IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia.
Zachary R. Hunter, Robert J. Manning, Christine Hanzis, Bryan T. Ciccarelli, Leukothea Ioakimidis, Christopher J. Patterson, Megan C. Lewicki, Hsuiyi Tseng, Ping Gong, Xia Liu, Yangsheng Zhou, Guang Yang, Jenny Sun, Lian Xu, Patricia Sheehy, Massimo Morra, and Steven P. Treon

[blood-2009-05-174359v1] How I Treat Waldenstrom's Macroglobulinemia.
Steven P. Treon

[CLM_2009.n.001] Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden. Steven P. Treon, Christopher J. Patterson, Eva Kimby, Marvin J. Stone

[CLM_2009.n.014] Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenström's Macroglobulinemia. Bryan T. Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, Leukothea Ioakimidis, Christopher J. Patterson, Robert J. Manning, Lian Xu, Xia Liu, Hsiuyi Tseng, Ping Gong, Jenny Sun, Yangsheng Zhou, Steven P. Treon

[CLM_2009.n.016] Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia. Leukothea Ioakimidis, Christopher J. Patterson, Zachary R. Hunter, Jacob D. Soumerai, Robert J. Manning, Barry Turnbull, Patricia Sheehy, Steven P. Treon

[JCO.2008.20.4677v1] Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Patricia Sheehy, Marybeth Nelson, Michael Willen, Jeffrey Matous, John Mattern II, Jakow G. Diener, George P. Keogh, Thomas J. Myers, Andy Boral, Ann Birner, Dixie L. Esseltine, and Irene M. Ghobrial

[bjh_7592] Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Xavier Leleu, Zachary R. Hunter, Lian Xu, Aldo M. Roccaro, Anne-Sophie Moreau, Daniel D. Santos, Evdoxia Hatjiharissi, Vinod Bakthavachalam, Sophia Adamia, Allen W. Ho, Jacob Soumerai, Christopher J. Patterson, Robert J. Manning, Susanna Hamilton, Sigitas Verselis, Edward Fox, Ruben Carrasco, Irene M. Ghobrial and Steven P. Treon

[blood-2008-08-174961v1] International prognostic scoring system for Waldenstrom's macroglobulinemia. Pierre Morel, Alain Duhamel, Paolo Gobbi, Meletios A. Dimopoulos, Madhav V. Dhodapkar, Jason McCoy, John Crowley, Enrique M. Ocio, Ramon Garcia-Sanz, Steven P. Treon, Veronique Leblond, Robert A. Kyle, Bart Barlogie and Giampaolo Merlini

[Biologies: Targets & Therapy 2008:2(3)419-431] Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
Roccaro AM, Ghobrial IM, Blotta S, Treon SP, Malagola M, Anderson KC, Richardson PG, Russo D.

[JCO.2007.15.1530v1] Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs. Xavier Leleu, Jacob Soumerai, Aldo Roccaro, Evdoxia Hatjiharissi, Zachary R. Hunter, Robert Manning, Bryan T. Ciccarelli, Antonio Sacco, Leukothea Ioakimidis, Sophia Adamia, Anne-Sophie Moreau, Christopher J. Patterson, Irene M. Ghobrial, and Steven P. Treon

[JCO.2008.17.7865v2] Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. Meletios Athanasios Dimopoulos, Morie A. Gertz, Efstathios Kastritis, Ramon Garcia-Sanz, Eva K. Kimby, Veronique LeBlond, Jean-Paul Fermand, Giampaolo Merlini, Pierre Morel, Enrica Morra, Enrique M. Ocio, Roger Owen, Irene M. Ghobrial, John Seymour, Robert A. Kyle, and Steven P. Treon

[Blood. 2008 Nov 17] Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E.

[Blood. 2008 Nov 3] Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP.

[Blood. 2008 Sep 24] Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom's macroglobulinemia. Adamia S, Reichert AA, Kuppusamy H, Kriangkum J, Ghosh A, Hodges JJ, Pilarski PM, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM.

[Blood. 2008 Aug 19] Thalidomide and rituximab in Waldenstrom's macroglobulinemia. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Briccetti FM, Pasmantier M, Zimbler H, Cooper RB, Moore M, Hill J 2nd, Rauch A, Garbo L, Chu L, Chua C, Nantel SH, Lovett DR, Boedeker H, Sonneborn H, Howard J, Musto P, Ciccarelli BT, Hatjiharissi E, Anderson KC.

[Br J Haematol. 2008 Sep;142(5):775-85] The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP.

[Leuk Lymphoma. 2008 Jun;49(6):1104-7] Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM.

[Clin Cancer Res. 2008 Mar 15;14(6):1849-58] Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP.

[Blood. 2008 May 15;111(10):5068-77] Targeting NF-kappaB in Waldenstrom macroglobulinemia. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM.

[Eur J Haematol. 2008 Jun;80(6):503-9] Clinical relevance of soluble HLA class I molecules in Waldenstrom Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Le Friec G, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X.

[Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1157-60] Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. Menke MN, Feke GT, McMeel JW, Treon SP.

[Blood. 2008 May 1;111(9):4752-63] Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM.

[Cancer Treat Res. 2008;142:211-42. Review. No abstract available] Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma. Treon SP, Hatjiharissi E, Merlini G.

[Blood. 2008 Jan 23] CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia. Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP.

[Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S199-206] Novel agents in the treatment of Waldenström's macroglobulinemia. Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson

[Blood. 2007 Dec 15;110(13):4417-26] The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM.

[Exp Hematol. 2007 Sep;35(9):1366-75] Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP.

[Clin Cancer Res. 2007 Jun 1;13(11):3320-5] Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A.

[Blood. 2007 Oct 1;110(7):2561-4] Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP.

[Cancer Res. 2007 Apr 15;67(8):3777-84] Proteomic analysis of waldenstrom macroglobulinemia. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM.

[Clin Cancer Res. 2007 Apr 1;13(7):2005-13] Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM.

[Clin Lymphoma Myeloma. 2007 Jan;7(4):286-90] Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, Treon SP.

[Blood. 2007 Jun 1;109(11):4964-72] Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM.

[Am J Hematol. 2007 Jan;82(1):83-4] Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Leleu X, O'Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP.

[Clin Cancer Res. 2006 Dec 1;12(23):7174-9] Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.

[Arch Ophthalmol. 2006 Nov;124(11):1601-6] Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. Menke MN, Feke GT, McMeel JW, Branagan A, Hunter Z, Treon SP.

[Blood. 2006 Oct 15;108(8):2804-10] Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC.

[Clin Lymphoma Myeloma. 2006 May;6(6):478-83] CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP.

[Ann Oncol. 2006 Aug;17(8):1275-82] Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP.

[Clin Infect Dis. 2006 Jul 1;43(1):16-24] Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR.

[Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3] Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Bladé J.

[Blood. 2006 May 1;107(9):3442-6] Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ.

[Ann Oncol. 2006 Mar;17(3):488-94] Characterization of familial Waldenstrom's macroglobulinemia. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC.

[Cancer Res. 2005 Dec 15;65(24):11712-20] Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC.

[Blood. 2005 Aug 15;106(4):1341-5] A SCID-hu in vivo model of human Waldenström macroglobulinemia. Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, Munshi V, Venuta S, Anderson KC, Treon SP, Munshi NC.

[Clin Lymphoma. 2005 Mar;5(4):273-7] CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Treon SP, Hunter Z, Barnagan AR.

[Clin Lymphoma. 2005 Mar;5(4):253-6] Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. Adamia S, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, Belch AR, Pilarski LM.

[Clin Lymphoma. 2005 Mar;5(4):246-9] CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Hunter ZR, Branagan AR, Manning R, Patterson CJ, Santos DD, Tournilhac O, Dorfman DM, Treon SP.

[Clin Lymphoma. 2005 Mar;5(4):215-6. No abstract available.] Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Treon SP, Morel P, Leblond V, Fermand JP.

[J Clin Oncol. 2005 Mar 1;23(7):1564-77] Diagnosis and management of Waldenstrom's macroglobulinemia. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP.

[J Clin Oncol. 2005 Jan 20;23(3):474-81] Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA.

[Br J Haematol. 2005 Jan;128(2):192-203] Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC.

[Ann Oncol. 2005 Jan;16(1):132-8] Extended rituximab therapy in Waldenström's macroglobulinemia. Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR; Waldenström's Macroglobulinemia Clinical Trials Group.

[Clin Lymphoma. 2004 Dec;5(3):205-7] Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Treon SP, Tournilhac O, Branagan AR, Hunter Z, Xu L, Hatjiharissi E, Santos DD.

[Hematology Am Soc Hematol Educ Program. 2004:257-82] Amyloidosis and Waldenström's macroglobulinemia. Gertz MA, Merlini G, Treon SP.

[Ann Oncol. 2004 Oct;15(10):1481-3] Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC.

[Cancer Res. 2004 Apr 15;64(8):2846-52] Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC.

[Br J Haematol. 2004 May;125(3):343-52] Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.

[Blood. 2004 Oct 1;104(7):2134-42] Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM.

[Cancer Res. 2003 Oct 15;63(20):6689-96] Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC.

[Br J Haematol. 2003 May;121(4):592-6] Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC.

[Semin Oncol. 2003 Apr;30(2):309-12] Novel biologically based therapies for Waldenstrom's macroglobulinemia. Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KC.

[Semin Oncol. 2003 Apr;30(2):248-52] Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Treon SP, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, Schlossman R, Mitsiades N, Mitsiades C, Preffer F, Anderson KC.

[Semin Oncol. 2003 Apr;30(2):156-60] Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Mitsiades CS, Mitsiades N, Treon SP, Anderson KC.

[Semin Oncol. 2003 Apr;30(2):132-5] The malignant clone in Waldenstrom's macroglobulinemia. Kriangkum J, Taylor BJ, Mant MJ, Treon SP, Belch AR, Pilarski LM.

[Semin Oncol. 2003 Apr;30(2):127-31] Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Bladé J, Kimby E.

[Semin Oncol. 2003 Apr;30(2):121-6] Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Gertz MA, Anagnostopoulos A, Anderson K, Branagan AR, Coleman M, Frankel SR, Giralt S, Levine T, Munshi N, Pestronk A, Rajkumar V, Treon SP.

[Semin Oncol. 2003 Apr;30(2):116-20] Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M, Lister TA, Merlini G, Morel P, Stone M, Branagan AR, Leblond V.

[Semin Oncol. 2003 Apr;30(2):110-5] Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA.

[Semin Oncol. 2003 Apr;30(2):107-9. No abstract available] Defining Waldenstrom's macroglobulinemia. Treon SP, Dimopoulos M, Kyle RA.

[Blood. 2003 Apr 1;101(7):2762-9] CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC.

[Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9] Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.

[Oncogene. 2002 Aug 22;21(37):5673-83] Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.

[Blood. 2002 Jun 15;99(12):4525-30] Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC.

[Blood. 2002 Jun 1;99(11):4079-86] Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC.

[J Immunother. 2002 Jan-Feb;25(1):72-81] CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC.

[Blood. 2002 Mar 15;99(6):2162-71] Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.

[Expert Opin Investig Drugs. 2001 Aug;10(8):1521-30] Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.

[Leukemia. 2001 Dec;15(12):1950-61] Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC.

[Blood. 2001 Aug 1;98(3):795-804] TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.

[Blood. 2001 Jul 1;98(1):210-6] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC.

[J Immunother (1991). 2001 May;24(3):272-279] CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.

[J Immunother (1991). 2001 May;24(3):263-271] Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.

[J Immunother. 2001 May-Jun;24(3):272-9] CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.

[J Immunother. 2001 May-Jun;24(3):263-71] Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.

[Semin Oncol. 2000 Dec;27(6 Suppl 12):79-85] The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Treon SP, Anderson KC.

[J Immunol. 2000 Dec 1;165(11):6347-55] Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, Anderson KC.

[Blood. 2000 Nov 1;96(9):3147-53] Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Treon SP, Maimonis P, Bua D, Young G, Raje N, Mollick J, Chauhan D, Tai YT, Hideshima T, Shima Y, Hilgers J, von Mensdorff-Pouilly S, Belch AR, Pilarski LM, Anderson KC.

[Blood. 2000 Nov 1;96(9):2943-50] Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC.

[Semin Oncol. 2000 Oct;27(5):598-613] Immunotherapeutic strategies for the treatment of plasma cell malignancies. Treon SP, Raje N, Anderson KC.

[Amyloid. 2000 Jun;7(2):126-32] Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Raje N, Kica G, Chauhan D, Zhang Y, Teoh G, Treon SP, Hideshima T, Deng JH, Gao SJ, Alsina M, Wally J, Davies FE, Tai YT, Pinkus GS, Pinkus JL, Skinner M, Comenzo RL, Anderson KC.

[Clin Cancer Res. 2000 Mar;6(3):1180-9] Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Hideshima T, Chauhan D, Teoh G, Raje N, Treon SP, Tai YT, Shima Y, Anderson KC.

[Ann Oncol. 2000;11 Suppl 1:107-11] Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Treon SP, Shima Y, Grossbard ML, Preffer FI, Belch AR, Pilarski LM, Anderson KC.

[J Immunol Methods. 2000 Feb 21;235(1-2):11-9] Isolation and characterization of human multiple myeloma cell enriched populations. Tai YT, Teoh G, Shima Y, Chauhan D, Treon SP, Raje N, Hideshima T, Davies FE, Anderson KC.

[Blood. 2000 Feb 1;95(3):1039-46] CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Anderson KC.

[Semin Oncol. 1999 Oct;26(5 Suppl 14):97-106] Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC.

[Blood. 1999 Mar 1;93(5):1487-95] Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, Anderson KC.

[Blood. 1999 Mar 1;93(5):1482-6] Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Chauhan D, Bharti A, Raje N, Gustafson E, Pinkus GS, Pinkus JL, Teoh G, Hideshima T, Treon SP, Fingeroth JD, Anderson KC.

[Blood. 1999 Feb 15;93(4):1287-98] Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC.

[Blood. 1998 Sep 1;92(5):1749-57] Anti-estrogens induce apoptosis of multiple myeloma cells. Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, Anderson KC.

[J Clin Invest. 1998 Mar 15;101(6):1379-88] The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. Teoh G, Urashima M, Greenfield EA, Nguyen KA, Lee JF, Chauhan D, Ogata A, Treon SP, Anderson KC.

[Curr Opin Hematol. 1998 Jan;5(1):42-8] Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Treon SP, Anderson KC.

[Clin Cancer Res. 1997 Nov;3(11):2173-9] Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Urashima M, Teoh G, Ogata A, Chauhan D, Treon SP, Sugimoto Y, Kaihara C, Matsuzaki M, Hoshi Y, DeCaprio JA, Anderson KC.

[Leukemia. 1997 Nov;11(11):1957-63] Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. Urashima M, Teoh G, Ogata A, Chauhan D, Treon SP, Hoshi Y, DeCaprio JA, Anderson KC.

[Blood. 1997 Nov 15;90(10):4106-15] p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. Urashima M, DeCaprio JA, Chauhan D, Teoh G, Ogata A, Treon SP, Hoshi Y, Anderson KC.

[Blood. 1997 Sep 1;90(5):1982-92] MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP, Schlossman RL, Anderson KC.

[J Immunol. 1997 Sep 1;159(5):2212-21] IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC.

[Blood. 1997 Jul 15;90(2):754-65] The development of a model for the homing of multiple myeloma cells to human bone marrow. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC.

[Blood. 1997 Jul 1;90(1):279-89] Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC.

[Clin Cancer Res. 1997 Jun;3(6):1017-22] Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC.

[Clin Chem. 1996 Aug;42(8 Pt 2):1322-9] Concepts in use of high-dose methotrexate therapy. Treon SP, Chabner BA.

[Leuk Res. 1994 Jan;18(1):17-21] CD14 mediated endogenous TNF-alpha release in HL60 AML cells: a potential model for CD14 mediated endogenous cytokine release in the treatment of AML. Treon SP, Anand B, Ulevitch R, Broitman SA.

[Proc Soc Exp Biol Med. 1993 Feb;202(2):153-8] Lipopolysaccharide (LPS) processing by Kupffer cells releases a modified LPS with increased hepatocyte binding and decreased tumor necrosis factor-alpha stimulatory capacity. Treon SP, Thomas P, Broitman SA.

[Med Hypotheses. 1992 Nov;39(3):238-42] Monoclonal antibody therapy in the treatment of Reye's syndrome. Treon SP, Broitman SA.

[Leukemia. 1992 Oct;6(10):1036-42] Beneficial effects of post-transfusional hepatitis in acute myelogenous leukemia may be mediated by lipopolysaccharides, tumor necrosis factor alpha and interferon gamma. Treon SP, Broitman SA.

[Leukemia. 1992;6 Suppl 3:141S-145S] Growth restraint and differentiation by LPS/TNF-alpha/IFN-gamma reorganization of the microtubule network in human leukemia cell lines. Treon SP, Anand B, Chou IN, Broitman SA.